TPST2

Across TCGA pan-cancer cohorts, TPST2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TPST2 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TPST2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TPST2 expression acts as an unfavorable survival marker.

GBM, HNSC, and PRAD are the cancer types where TPST2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.069	0.415	<.001	12	view →
HNSC	OS	Median	All	0.185	0.685	.036	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TPST2–GBM (OS)

Open the GBM breakdown →